New York, May 19, 2014 -- Moody's Investors Service commented that the new proposal by Pfizer Inc. to acquire AstraZeneca PLC for GBP55 per share in stock and cash is credit positive, even though the cash portion of the proposal is significantly higher than Pfizer's previous proposals. There is no immediate impact on Pfizer's A1 long-term or Prime-1 short term ratings at this time.
Vollständigen Artikel bei Moodys lesen